Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2000-04-12
2003-05-20
Carlson, Karen Cochrane (Department: 1653)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C530S351000, C536S024100, C435S069500, C435S071100
Reexamination Certificate
active
06566501
ABSTRACT:
BACKGROUND OF THE INVENTION
The innate host response to bacterial pathogens is characterized by an immediate release of biologically active compounds, including monokines and cytokines. These proinflammatory molecules, which are intended to enable the host to eliminate the pathogen, may also adversely affect the host. In acute situations, the pathogen is often eliminated, with resolution of inflammation and minimal tissue damage. However, failure to control the pathogen often leads to a state of metabolic anarchy in which the inflammatory response is not controlled and significant tissue damage results. Endotoxins, produced from the outer membrane of Gram-negative bacteria, and exotoxins, released from the cell wall of Gram-positive bacteria, are known to be potent inducers of the inflammatory response. Lipopolysaccharide (LPS), extracted from the outer membrane of Gram-negative bacteria, has been identified as a principal endotoxic component.
Although the inflammatory response is mediated by a variety of secreted factors, the cytotoxic effects of LPS have been ascribed to TNF-&agr; activity (Beutler et al.,
Science
229: 869-871 (1985); Tracey et al.,
Science
234: 470-474 (1986); Miethke et al.,
J. Exp. Med.
175: 91-98 (1992)). TNF-&agr; is a pleiotropic cytokine which serves to either benefit the host or in some situations exert detrimental effects on the host (Beutler and Cerami,
Nature
320: 584-588 (1986); Beutler et al.,
Science
232: 977-980 (1986); Beutler and Cerami,
N. Engl. J. Med.
316: 379-385 (1987)). TNF-&agr; benefits the host by helping to prevent cancer, protecting against infection, promoting tissue remodeling, and activating inflammatory responses. Conversely, in host responses which have gone awry, TNF-&agr; mediates septic shock in chronic infections, is responsible for cachexia in cancer patients, causes inflammation in rheumatoid arthritis patients, and activates the human immunodeficiency virus. The pleiotropic effects of TNF-&agr; are dose-dependent. Hence, the perceived need to control TNF-&agr; production has raised interest into the understanding of the mechanisms that modulate TNF-&agr; gene expression.
It is well known that gene transcription is controlled by DNA-binding proteins. Recently, several groups have examined the transcriptional regulation of TNF-&agr; by various inducers, such as virus, LPS, and PMA. The human TNF-&agr; promoter contains motifs that resemble nuclear factor kappa B (NF-&kgr;B) binding sites; however, controversy exists as to the involvement of NF-&kgr;B in TNF-&agr; gene regulation. The nature of the nuclear factor(s) involved in the regulation of LPS-induced TNF-&agr; gene expression in humans remains unknown.
SUMMARY OF THE INVENTION
In one aspect, the present invention relates to an isolated polypeptide which binds to the DNA binding domain located from −550 to −487 in the promoter of the human TNF-&agr; gene. This isolated polypeptide is referred to herein as the LITAF protein. In one embodiment, the isolated polypeptide is mammalian in origin. In a preferred embodiment, it is human or murine.
In another aspect the present invention relates to a nucleic acid sequences which encodes the LITAF protein. Nucleic acid sequences which are characterized by the ability to hybridize to the complement of the nucleic acid sequence of the present invention under stringent hybridization conditions are also encompassed by the present invention. Also encompassed is an expression vector comprising a nucleic acid sequence which encodes the LITAF protein. Also encompassed is a cell containing said expression vector, and a mammalian gene which encodes the LITAF protein. Preferably, the gene is human and is located on Chromosome 16 p12-16p13.3.
In another aspect, the present invention relates to an antibody characterized by the ability to specifically bind to the LITAF protein. The antibody may be monoclonal or polyclonal.
Another aspect of the present invention relates to a method for inhibiting LITAF dependent induction of TNF-&agr; gene expression in a cell, comprising the steps a) providing an inhibitor of expression of the LITAF gene; and b) delivering the inhibitor into the cell. In one embodiment, the inhibitor is an antisense construct which encodes an antisense RNA molecule which is complementary to a portion of the LITAF mRNA which is greater than 200 nucleotides in length. Preferably, the antisense RNA molecule is complementary to the start site of translation, upstream adjacent 5′ untranslated sequence, and downstream adjacent coding sequence of the LITAF mRNA. Optimal lengths and specific nucleotides for complementary are discussed.
Another aspect of the present invention relates to a method for inhibiting LITAF dependent induction of TNF-&agr; gene expression in a cell comprising the steps a) providing an inhibitor of LITAF protein function; and b) contacting the inhibitor to the LITAF in the cell. In one embodiment, the inhibitor is an antibody which binds the LITAF protein. In another embodiment the inhibitor is a small molecule which inhibits the function of the LITAF protein. One example of such an inhibitor is a recombinant mutant LITAF protein.
Therapeutic methods for treating a patient with a disease associated with chronic inflammation, by administration of the LITAF inhibitor to the patient are also provided. Such diseases include rheumatoid arthritis, gum disease Crohn's disease, and graft-versus-host disease. Therapeutic methods for treating a patient with a disease in which TNF-&agr; plays a role in pathology are also provided. Examples of such diseases are diabetes mellitus, cancer, cachexia, breast cancer, HIV, sepsis, malaria, trypanomiasis and asthma. Other methods provided include a method for identifying gene which are regulated by the LITAF protein, a method for identifying a molecule which inhibits LITAF binding to the TNF-&agr; promoter, and a method for identifying molecules which bind LITAF from a protein array.
REFERENCES:
Myokai et al. “A novel lipopolysaccharide-induced transcription factor regulating tumor necrosis factor alpha gene expression: Molecular cloning, sequencing, characterization, and chromosomal assignment”, Proc.Natl.Acad.Sci.USA, 96, pp. 4518-4523, 1999.*
Takashiba et al.,Infect. Immun. 63: 1529-1534 (1995).
Neuenschwander et al.,Endocrinology 136: 4298-4303 (1995).
Stein, C.A.,Antisense and Nucleic Acid Drug Dev. 8: 129-132 (1998).
Hélène et al.,Ciba Foundation Symposium 209: 94-102 (1997).
Agrawal and Iyer,Pharm. Ther. 76: 151-160 (1997).
Yao et al.,J. of Biol. Chem. 272(28): 17795-801 (1997).
Beutler et al.,Science 229: 869-871 (1985).
Tracey et al.,Science 234: 470-474 (1986).
Miethke et al.,J. Exp. Med. 175: 91-98 (1992).
Tracey et al.,J. Exp. Med. 167: 1211-1227 (1988).
Rink and Kirchner,Int. Arch. Allergy Immunol. 111: 199-209 (1996).
Polyak et al.,Nature, Sep. 18; 389(6648): 300-305 (1997).
Amar and Myokai, GenBank deposit U77396 (1996).
Amar and Myokai, GenBank deposit NM 004862 (1996).
Carlson Karen Cochrane
Farrell Kevin M.
Mitra Rita
Pierce Atwood
Trustees of Boston University Boston
LandOfFree
Transcription factor regulating TNF-&agr; does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Transcription factor regulating TNF-&agr;, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Transcription factor regulating TNF-&agr; will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3049021